Pharming Group NV Addresses Shareholders' Queries Ahead of AGM: Discusses Acquisition of Abliva, U.S. Market Focus, and Future Prospects
Reuters
Sep 08
<a href="https://laohu8.com/S/PHGUF">Pharming Group NV</a> Addresses Shareholders' Queries Ahead of AGM: Discusses Acquisition of Abliva, U.S. Market Focus, and Future Prospects
During the Annual General Meeting of Pharming Group NV held on June 11, 2025, key discussions revolved around the company's strategic decisions and market positioning. A representative of the Dutch Investors Association, Mr. Keyner, questioned how Pharming managed to acquire Abliva and its promising medicine, KL1333, when other market players did not recognize its potential. Additionally, he inquired whether Pharming should focus solely on its U.S. operations given its unique market position compared to major pharmaceutical companies. In response, Mr. Chouraqui, the newly appointed Executive Director and CEO, expressed excitement about the acquisition and highlighted Pharming's commitment to exploring diverse strategies to mitigate risks. The Chairman assured shareholders that the Board is closely monitoring developments and staying informed. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.